Shares of Moderna Inc. MRNA inched 0.55% higher to $53.09 Friday, on what proved to be an all-around mixed trading session ...

Moderna (NASDAQ:MRNA) shares traded in the green on Friday, snapping six consecutive days of losses. The stock closed up 0.55 ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

For a drugmaker advancing medicines through clinical trials, time is the enemy: the longer the process takes, the more costs ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

Many people don’t know they’re eligible. | Moderna has identified a fundamental barrier to vaccination: many people don’t ...

Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused ...

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), ...

UBS lowered the firm’s price target on Moderna (MRNA) to $108 from $140 and keeps a Buy rating on the shares following a model review.

Anticipated earnings release is in 16 days. A total of 2 professional analysts have given their take on this stock in the ...

The biotech industry is buzzing with exciting changes, and a lot of it is thanks to one company: Moderna. Known for its COVID ...

CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global ...